Tiprogrel
- Generic Name
- Tiprogrel
Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
- Target Recruit Count
- 600
- Registration Number
- NCT06601127
- Locations
- 🇨🇳
Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning, China
🇨🇳Beijing Tiantan Hosptial, Capital Medical University, Beijing, China
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
Phase 1
Completed
- Conditions
- Acute Coronary SyndromeIschemic Stroke
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
- Target Recruit Count
- 14
- Registration Number
- NCT06584812
- Locations
- 🇨🇳
Beijing Tiantan Hosptial, Capital Medical University, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath